The federal agency introduced Elsa last month, boasting about the AI tool's ability to increase efficiency at the FDA.

The FDA is still on track to meet its user fee targets despite a higher-than-normal vacancy rate among scientific reviewers.

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

In 2024, HR leaders faced unprecedented pressure from senior executives concerned about continually rising healthcare costs.

Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

Dr. Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research, urged public health leaders ...

The American Benefits Council is urging Congress to consider the cost to employers, workers and their families as it proposes ...

When Sarah told her elderly mother about what she had found, she was horrified to hear that James had also been sexually coercive towards her. It was only when Sarah took him to see his specialist ...

Moses reported same-store growth of 8.6% in the CCRC business, driven by rate growth of 5% and higher entrance fee sales. Outpatient medical achieved 85% tenant retention, a positive rent ...

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...

Q2 2025 Earnings Call Transcript July 24, 2025 Labcorp Holdings Inc. misses on earnings expectations. Reported EPS is $2.83 ...